resistance to low to moderate plasma level of aminoglycosides.
There is no single solution to fight the spread of antimicrobial resistant pathogens, but multiple interventions have demonstrated potential benefit.
The corn stone of all strategies for prevention of antimicrobial resistance spread is the knowledge of physicians and other healthcare providers of the importance of the problem.
One strategy for reduction of drug resistance is to allow "difficult-to-treat" pathogens be exposed to bactericidal drug concentrations via dose optimization.
In the case of aminoglycosides, The best parameter that determines the in-vivo exposure of the pathogen to serum aminoglycoside concentrations is the ratio between the peak and the minimum inhibitory concentration (MIC) (peak/MIC) of the causative gram-negative pathogen.
When the peak is 8 to 10 times greater than the MIC, the best antibiotic response is achieved. Taccone et al. showed that because of increased volume of distribution (Vd) in patients with severe sepsis and septic shock, an initial dose of ≥ 25 mg/kg TBW of amikacin is needed to reach therapeutic peak concentrations.
Besides, patients generally undergo various empiric antimicrobial regimens that therefore prone them to develop antimicrobial resistance because of poorly controlled antibiotic prescription and lack of a well-defined antimicrobial treatment protocol in pre-ICU as well as ICU settings in our country.
Since 2001, different societies have tried to draw attention to the significant lack of new antibiotics for Gram-negative pathogens. In fact, in 2004 the infectious disease society of America issued their report, Bad Bugs, No Drugs.
Unfortunately, drugs in late stage development, as well as the recently approved Doripenem, offer little advantage over already existing carbapenems for treating infections due to extended expectrum beta-lactamase producing bacteria. Thus, tigecycline and the polymixins including colistin, have been used with variable success rates .
The incidence of infections due to multiple drug resistance (MDR) acinetobacter spp. Continues to increase in our ICUs, and others with almost no agent currently under research or development pipeline.
Thus, according to CDC campaign preventive approaches includes: preventing health careassociated infections, optimizing the specific diagnosis and treatment of infections, optimizing use of antimicrobial agents including improving the choice, dose, and duration of therapy, and preventing cross-transmission of resistant pathogens.
Besides, antimicrobial susceptibility/resistance should be determined and a special antimicrobial treatment protocol should be planned based on the results for each ICU. The best resistance control requires a team wok between clinical microbiology, an infection prevention program, clinical pharmacists and clinicians.
